等待開盤 06-25 09:30:00 美东时间
+0.065
+0.26%
BRIEF-Vedana Therapeutics Emerges From Stealth With $46 Mln Series A Financing June 17 (Reuters) - Vedana Therapeutics: VEDANA THERAPEUTICS: PROCEEDS TO BE USED TO ADVANCE CO'S PORTFOLIO OF ANTIBODIES TARGETING CLINICALLY VALIDATED PATHWAYS FOR MIGRAINE PREVENTION VEDANA THERAPEUTICS: FINANCING CO-L
06-17 17:00
Dana posts presentation on planned combination with Eaton Mobility Group via Reverse Morris Trust transaction Dana outlined plans to combine with Eaton’s Mobility Group via a Reverse Morris Trust, creating a powertrain platform with implied enterprise value above $10 billion. Eaton Mobility valued a
06-11 18:57
Dana agrees to combine with Eaton Mobility business in USD 5.1 billion deal Dana will combine with Eaton’s Mobility business in a deal valuing Eaton Mobility at about USD 5.1 billion. Pro forma 2026 profile: about USD 11 billion sales, about USD 1.7 billion adjusted EBITDA, about 15% margin. Eaton s
06-11 18:30
Dana to join UBS Auto and Auto Tech Conference fireside chat Dana will participate in the UBS Auto and Auto Tech Conference on June 3. Incoming CEO Byron Foster will join Chairman R. Bruce McDonald for a 40-minute fireside chat starting at 1 p.m. EDT. Disclaimer: This news brief was created by Publi
05-28 22:00
Dana (NYSE:DAN) reported first-quarter financial results on Wednesday. The tran...
04-29 21:49
Dana Q1 adjusted EBITDA jumps to $171 million; sales rise 5% to $1.9 billion Dana posted first-quarter 2026 revenue of $1.9 billion, up 5%. Adjusted EBITDA jumped to $171 million, lifting adjusted EBITDA margin 400 basis points to 9.2%. Operating cash flow was a use of $156 million; adjusted free ca
04-29 18:59
Sedana Medical AB ( ($SE:SEDANA) ) has shared an update. Sedana Medical reporte...
04-23 13:36
DANA published its Capital Markets Day presentation; 2030 sales target rises to ~$10.0 billion Dana outlined 2030 financial targets, with sales rising to about $10 billion and adjusted EBITDA margin increasing to 14%-15%. Adjusted FCF margin climbs to about 6%. Share repurchase target through 2030 t
03-25 19:12
Dana hosts 2026 Capital Markets Day; Dana 2030 sales target rises to $10.0 billion by 2030 Dana hosted its 2026 Capital Markets Day in New York City, where executives outlined the Dana 2030 growth and value-creation strategy. The plan targets approximately $10.0 billion in annual sales by 2030 and a
03-25 18:59
Dana FY2030 sales rise to $10.0 billion; adjusted EBITDA margins widen to 14%-15% Dana outlined its “Dana 2030” strategy with a target of approximately $10.0 billion in annual sales by 2030. Adjusted EBITDA margins are expected to rise to 14% to 15%. Adjusted free cash flow margin is set to grow to
03-25 18:59